<DOC>
	<DOCNO>NCT00464516</DOCNO>
	<brief_summary>The study design single-center , randomize , double-blind , placebo-controlled study pre- postmenopausal woman undergo surgery breast cancer . Subjects either receive estetrol placebo 2 week treatment period . Several biological marker , cellular growth marker cell death marker , assess tumor tissue surround normal tissue treatment period . During 2 week interval diagnosis breast cancer surgical resection , therapy breast cancer usually administer .</brief_summary>
	<brief_title>Preoperative Estetrol Breast Cancer</brief_title>
	<detailed_description>The study design single-center , randomize , double-blind , placebo-controlled study pre- postmenopausal woman undergo surgery breast cancer . Subjects either receive estetrol placebo 2 week treatment period . Several biological marker , cellular growth marker cell death marker , assess tumor tissue surround normal tissue treatment period . In addition , receptor study perform . During 2 week interval diagnosis breast cancer surgical resection , therapy breast cancer usually administer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm diagnosis early invasive primary breast cancer ( clinically stage I II ; T1 T2 ; N01 ; M0 , require surgery ) . 2 . The malignant tumor must estrogen receptor ( ER ) positive determine local pathologist . Weak , intermediate strong staining consider appropriate inclusion . 3 . The breast tumor size must adequate core cut biopsy obtain sufficient amount tissue gene protein expression analysis . 4 . Subjects either pre postmenopausal . The postmenopausal study group define follow : old 70 year age natural menopause last menstrual bleeding least 12 month start study . If date last menstruation uncertain perimenopausal HRT case past hysterectomy intact ovary , subject must appropriate FSH Estradiol ( E2 ) level ( FSH &gt; 40 International Units ( IU ) /L E2 &lt; 20 pg/ml ( =73.40 pmol/l ) ) completion HRT washout accord exclusion criterion 2 3 . The premenopausal study group define follow : At least 18 year old 50 year age least one spontaneous menstrual bleeding last 6 month , combine FSH level 10 IU/L . Before treatment start pregnancy test perform negative . If appropriate barrier method contraception use duration study . The criterion perimenopausal HRT washout accord exclusion criterion 2 3 . 5 . BMI must 18 32 kg/m2 . 6 . The patient must provide voluntary write informed consent . 1 . Any serious disease ( e.g . severe liver renal disease ) , clinically significant abnormal laboratory value ( e.g . abnormal serum liver enzyme concentration upper safety limit ) clinically significant abnormality , investigator 's opinion , may lead adverse event course trial 2 . Previous use estrogen/progestogen within : 6 month depot preparation . 8 week oral preparation progestogen contain IUD . 4 week transdermal preparation 3 . Use hormone contain implant time 4 . Contraindications use steroid : A history , exist thromboembolic , cardiovascular cerebrovascular disorder . A history , exist condition predispose , prodromi , thrombosis . A known defect blood coagulation system ( e.g . deficiency ATIII , protein C , S , APC resistance ) . A medical history positive presence one risk factor vascular disease ( e.g . dyslipoproteinemia ; diabetes mellitus ; hyperhomocysteinemia ; systemic lupus erythematosus ; chronic inflammatory bowel disease ; smoking ; venous thromboembolism sibling parent age 50 , arterial disease sibling parent age 3035 ) . Hypertension , i.e . systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 100 mm Hg . Disturbance liver function : cholestatic jaundice , history jaundice pregnancy jaundice due previous estrogen use , Rotor syndrome DubinJohnson syndrome . Any previous hormonerelated malignancy within last 5 year . History presence endometrial cancer . Exceptions basaliomas skin intraepithelial cervical neoplasia ( CIN13 ) . Undiagnosed vaginal bleeding . Porphyria . A history pregnancy previous estrogen use severe pruritus , herpes gestationis deterioration otosclerosis . 5 . Presence significant allergy 6 . Administration investigational drug within 3 month start study medication 7 . A history ( within 12 month ) alcohol drug abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Breast cancer ( Estrogen Receptor positive )</keyword>
</DOC>